APR Nov/Dec 2022 - 83

« SECTION TITLE
Drug Delivery Composition
Comprising a Self-Assembled Gelator;
J.M. Karp, P.K. Vemula, G. John, and
G. Cruikshank; The Research Foundation
of the City University of New York, NY
and The Brigham and Women's Hospital,
Inc., Boston, MA; U.S. Patent # 11,471,515;
October 4, 2022.
This invention relates to low-molecular-weight amphiphilic
gelators. These gelators self-assemble into various nano- and
micro-structures in a wide range of organic and aqueous
solvents. The gelators also have the capability to deliver drugs.
This patent discloses drug-delivery compositions, methods of
making prodrugs, and methods of drug delivery using a selfassembled
gelator. The backbone of the gelator can contain a
drug or prodrug, such as acetaminophen or salicin. Additional
drugs or agents can be encapsulated in the gelator. Enzymatic
or hydrolytic cleavage can be used to release the drugs.
Restoration of Tumor Suppression
Using MRNA-Based Delivery System;
J. Shi, M.A. Islam, Y. Xu, O.C. Farokhzad,
and B. Zetter; The Brigham and Women's
Hospital and Children's Medical Center
Corp., Boston, MA; U.S. Patent
# 11,458,153; October 18, 2022.
Loss and/or mutation of tumor-suppressor genes is a dominant
force in tumor development and clinical resistance to a variety
of therapies. Restoring tumor-suppressor activity in cancer cells
is highly challenging and requires the design of a functionally
improved tumor suppressor with unique therapeutic modality.
Recently, chemically modified mRNA has emerged as an intriguing
alternative to DNA-based gene therapy. The delivery of mRNA
presents several potential challenges. The object of the present
invention is to provide nanotechnologies, which can be used to
deliver a therapeutic tumor suppressor mRNA or combinations of
different tumor suppressor mRNAs for cancer treatment. Patent
discloses compositions and methods for treating cancer that
include administering a therapeutically effective amount of a
tumor suppressor mRNA complexed with a delivery vehicle.
Oral Liquid Compositions
Comprising Amlodipine Besylate
and Methods of Using the Same;
N. R. Bhatt and A. Kapadia; ECI
Pharma, Fort Lauderdale, FL; U.S.
Patent # 11,452,690; September 27, 2022.
Amlodipine is mostly available as tablets. Just recently,
amlodipine suspension and solutions were approved. So far,
liquid dosage forms were prepared by compounding tablets into
a suspension and such formulations result in a variety of issues.
The current patent claims an oral liquid composition comprising:
0.1 to about 1.9 mg/mL amlodipine besylate, about 5 mg/mL to
about 90 mg/mL cyclodextrin, about 0.5 mg/mL to about 4 mg/
mL paraben and water. The composition may further include a
sweetener, a flavoring agent, a stabilizer, a coloring agent and a
thickener. It claims that the volume of this oral liquid composition
retains at least 90% of initial concentration of amlodipine after
the formulation has been stored in a sealed container for six
months at various storage conditions.
Aqueous Wound Healing Formulation;
H. Spanjer, K.J. Rivera, S. Maida, J.
Librizzi, and A. D'Ovidio; Advantice
Health, NJ; U.S. Patent # 11,446,256;
September 20, 2022.
Typical wound covers (textile or adhesive bandages) aim to
stop bleeding, promote healing and prevent contamination to
reduce risk of infection. These have many disadvantages, such
as dust collection, contamination, difficult application to certain
areas etc. Liquid bandages can eliminate some of these issues,
but have issues of their own such as the presence of organic
solvents, and toxic polymers, stinging sensation and harsh
scent. This patent claims an aqueous formulation comprising
a water-soluble polymeric material capable of adhering to
skin and acting as a barrier to moisture but not to oxygen, and
allowing water within the formulation to evaporate leaving a
film covering the injured area.
www.americanpharmaceuticalreview.com |
| 83
»
http://www.americanpharmaceuticalreview.com
APR Nov/Dec 2022

Table of Contents for the Digital Edition of APR Nov/Dec 2022
